RNS Number : 3364F
Synairgen plc
13 November 2020
Synairgen plc
("Synairgen" or the "Company")
Holding(s) in Company
Southampton, UK
,
: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, announces that it was informed on 13 November 2020 that Leonard Licht, a private investor, now holds less than 3% of the Company's issued share capital.
Enquiries:
Synairgen plc +44 (0) 23 8051 2800
Richard Marsden (Chief Executive Officer)
John Ward (Finance Director)
finnCap - Nominated Adviser and Joint Broker +44 (0) 20 7220 0500
Geoff Nash / Kate Bannatyne / Charlie Beeson (Corporate Finance)
Alice Lane / Sunila de Silva (ECM)
Numis - Joint Broker +44 (0) 20 7260 1000
James Black / Freddie Barnfield / Duncan Monteith
Consilium Strategic Communications - Financial Media and Investor +44 (0) 20 3709 5700
Relations Adviser
Mary-Jane Elliott / Sue Stuart / Olivia Manser
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END
HOLFLFIDLFLVLII
|
